On March 15, 2018 BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, reported that promising preclinical data with BerGenBio’s lead AXL inhibitor bemcentinib (formerly BGB324) will be featured at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting on 14-18 April in Chicago, USA (Press release, BerGenBio, MAR 15, 2018, View Source [SID1234525083]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data highlight bemcentinib’s potential to reverse tumour immune suppression and enhance immune checkpoint inhibitor efficacy. These data continue to support the clinical rationale for combining bemcentinib with immune checkpoint inhibitors to improve cancer treatment. BerGenBio is currently conducting three Phase II clinical trials evaluating bemcentinib in combination with the immune checkpoint inhibitor, KEYTRUDA.

Abstract ID#: 6026

Poster presentation: Tuesday Apr 17, 2018 8:00 AM – 12:00 PM, McCormick Place South, Exhibit Hall A, Poster Section 32

The abstract is now available online.